JPRN-UMIN000017079已完成1 期
Phase II Clinical Trial of Monotherapy with Irinotecan Hydrochloride (CPT-11) for Advanced or Recurrent Endometrial Cancer - Irinotecan For Endometrial Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1.Patients with a history of treatment with topoisomerase I inhibitors (irinotecan, nogitecan, etc.) 2.Patients with liver dysfunction (jaundice) or serious renal dysfunction 3.Patients with serious drug allergies (hypersensitivity) 4.Patients with active double cancers 5.Patients who have or are suspected to have clinically problematic infections 6.Patients with poorly controlled hypertension or diabetes mellitus 7.Patients who have marked electrocardiographic abnormalities or clinically problematic cardiac disease 8.Patients with severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema, etc.) 9.Patients with a history of clinically problematic mental disorders, central nervous system disorders, or cerebrovascular/cranial nerve disease 10. Patients with fresh gastrointestinal bleeding, intestinal paralysis, intestinal obstruction, or peptic ulcer 11.Patients with pleural effusion, ascites, or pericardial effusion requiring removal with the use of a drain 12.Patients with brain metastasis or who are suspected to have brain metastasis on the basis of clinical symptoms 13.Patients with diarrhea (watery stool) 14.Patients who are receiving atazanavir sulfate 15.Patients who are continuously receiving systemic administration of steroids (oral or intravenous infusion) 16.Pregnant women, breast-feeding women, or women who may (want to) become pregnant 17.Patients who are considered ineligible for participation in the study by the physician responsible (partially responsible) for treatment
研究者
相似试验
尚未招募
不适用
A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancercolonrectal cancerJPRN-UMIN000004659The University of Tokushima Graduate School35
已完成
2 期
Phase II study of combination therapy with Irinotecan and S-1 in patients with progressive colorectal cancer after FOLFOX regimenresectable advanced/recurrent colorectal cancerJPRN-UMIN000001342KSCC56
进行中（未招募）
不适用
Phase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration ? ICAND ? Trial - NDPKANEUCTR2008-003059-56-ITISTITUTO NEUROLOGICO CARLO BESTA
进行中（未招募）
1 期
Medical treatment for patients with cancer of the esophagus or stomachPatients with esophagus or gastric cancer and who are platinum resistant and non-resectabelMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002321-30-DKOdense University Hospital
进行中（未招募）
不适用
A clinical trial to compare tolerabilty and efficiacy (how well the drug works) of following treatments:Blocking liver arteries (chemoembolisation) by beads loaded with irinotecan (chemotherapeutic) and intravenous administration of cetuximab (chemotherapeutic) compared to administration of intravenous cetuximab and irinotecan in patients with k-ras (gene) wild-type tumors.Patients with unresectable liver metastases of colorectal cancer who previously failed pretreatment with 5FU/oxaliplatin and/or 5FU/irinotecan (2nd- or 3rd-line).MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014728-44-DEMartin Luther Universität Halle-Wittenberg80